Advertisement
05-03-2025 | Review Article
Expanding horizons in theragnostics: from oncology to multidisciplinary applications
Published in: La radiologia medica
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference Jadvar H et al (2018) Radiotheranostics in cancer diagnosis and management. Radiology 286(2):388–400PubMedCrossRef
Jadvar H et al (2018) Radiotheranostics in cancer diagnosis and management. Radiology 286(2):388–400PubMedCrossRef
2.
go back to reference Rizzo A, Annunziata S, Salvatori M (2022) Side effects of theragnostic agents currently employed in clinical practice. Q J Nucl Med Mol Imaging 65(4):315–326CrossRef
Rizzo A, Annunziata S, Salvatori M (2022) Side effects of theragnostic agents currently employed in clinical practice. Q J Nucl Med Mol Imaging 65(4):315–326CrossRef
3.
go back to reference Strosberg J et al (2017) Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125–135PubMedPubMedCentralCrossRef
Strosberg J et al (2017) Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125–135PubMedPubMedCentralCrossRef
4.
go back to reference Sartor O et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103PubMedPubMedCentralCrossRef
Sartor O et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103PubMedPubMedCentralCrossRef
5.
go back to reference Hofman MS et al (2024) Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncology 25(1):99–107PubMedCrossRef
Hofman MS et al (2024) Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncology 25(1):99–107PubMedCrossRef
6.
go back to reference Barthel H, Sabri O (2017) Clinical use and utility of amyloid imaging. J Nucl Med 58(11):1711–1717PubMedCrossRef
Barthel H, Sabri O (2017) Clinical use and utility of amyloid imaging. J Nucl Med 58(11):1711–1717PubMedCrossRef
7.
go back to reference Pagano G, Niccolini F, Politis M (2016) Imaging in parkinson”s disease. Clin Med 16(4):371–375CrossRef
Pagano G, Niccolini F, Politis M (2016) Imaging in parkinson”s disease. Clin Med 16(4):371–375CrossRef
8.
go back to reference Dai Y et al (2022) Acidity-activatable nanoparticles with glucose oxidase-enhanced photoacoustic imaging and photothermal effect, and macrophage-related immunomodulation for synergistic treatment of biofilm infection. Small 18(46):2204377CrossRef
Dai Y et al (2022) Acidity-activatable nanoparticles with glucose oxidase-enhanced photoacoustic imaging and photothermal effect, and macrophage-related immunomodulation for synergistic treatment of biofilm infection. Small 18(46):2204377CrossRef
9.
go back to reference Alphandéry E (2022) Nanomaterials as ultrasound theragnostic tools for heart disease treatment/diagnosis. Int J Mol Sci 23(3):1683PubMedPubMedCentralCrossRef
Alphandéry E (2022) Nanomaterials as ultrasound theragnostic tools for heart disease treatment/diagnosis. Int J Mol Sci 23(3):1683PubMedPubMedCentralCrossRef
10.
go back to reference Romero Y et al (2018) National cancer control plans: a global analysis. Lancet Oncol 19(10):e546–e555PubMedCrossRef
Romero Y et al (2018) National cancer control plans: a global analysis. Lancet Oncol 19(10):e546–e555PubMedCrossRef
11.
go back to reference Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J For Clin 71(3):209–249
Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J For Clin 71(3):209–249
12.
go back to reference Sgouros G et al (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discovery 19(9):589–608PubMedCrossRef
Sgouros G et al (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discovery 19(9):589–608PubMedCrossRef
13.
go back to reference Dekempeneer Y et al (2016) Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther 16(8):1035–1047PubMedPubMedCentralCrossRef
Dekempeneer Y et al (2016) Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther 16(8):1035–1047PubMedPubMedCentralCrossRef
14.
go back to reference Pomykala KL et al (2023) Next generation radiotheranostics promoting precision medicine. Ann Oncol: Off J Eur Soc Med Oncol 34(6):507–519CrossRef
Pomykala KL et al (2023) Next generation radiotheranostics promoting precision medicine. Ann Oncol: Off J Eur Soc Med Oncol 34(6):507–519CrossRef
15.
go back to reference Becker DV, Sawin CT (1996) Radioiodine and thyroid disease: the beginning. Semin Nucl Med 26(3):155–164PubMedCrossRef
Becker DV, Sawin CT (1996) Radioiodine and thyroid disease: the beginning. Semin Nucl Med 26(3):155–164PubMedCrossRef
16.
go back to reference Tuttle RM et al (2019) Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the american thyroid association, the european association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the european thyroid association. Thyroid : Off J Am Thyr Association 29(4):461–470CrossRef
Tuttle RM et al (2019) Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the american thyroid association, the european association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the european thyroid association. Thyroid : Off J Am Thyr Association 29(4):461–470CrossRef
17.
go back to reference Maruoka Y et al (2012) Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. Radiology 265(3):902–909PubMedCrossRef
Maruoka Y et al (2012) Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. Radiology 265(3):902–909PubMedCrossRef
18.
go back to reference Prado-Wohlwend S et al (2022) [177Lu]Lu-DOTA-TATE and [131I]MIBG phenotypic imaging-based therapy in metastatic/inoperable pheochromocytomas and paragangliomas: comparative results in a single center. Front Endocrinol 13:778322CrossRef
Prado-Wohlwend S et al (2022) [177Lu]Lu-DOTA-TATE and [131I]MIBG phenotypic imaging-based therapy in metastatic/inoperable pheochromocytomas and paragangliomas: comparative results in a single center. Front Endocrinol 13:778322CrossRef
19.
go back to reference Carlin S et al (2003) Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res : Off J Am Association For Cancer Res 9(9):3338–3344
Carlin S et al (2003) Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res : Off J Am Association For Cancer Res 9(9):3338–3344
20.
go back to reference Israeli RS et al (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Can Res 53(2):227–230
Israeli RS et al (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Can Res 53(2):227–230
21.
go back to reference Hupe MC et al (2018) Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol 8:623PubMedPubMedCentralCrossRef
Hupe MC et al (2018) Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol 8:623PubMedPubMedCentralCrossRef
22.
go back to reference Afshar-Oromieh A et al (2015) The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med: Off Publ, Soc Nucl Med 56(11):1697–1705CrossRef
Afshar-Oromieh A et al (2015) The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med: Off Publ, Soc Nucl Med 56(11):1697–1705CrossRef
23.
go back to reference Sartor O et al (2021) Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103PubMedPubMedCentralCrossRef
Sartor O et al (2021) Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091–1103PubMedPubMedCentralCrossRef
24.
go back to reference Almuradova E et al (2024) The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish oncology group multicenter study. Int J Cancer 154(4):692–700PubMedCrossRef
Almuradova E et al (2024) The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish oncology group multicenter study. Int J Cancer 154(4):692–700PubMedCrossRef
25.
go back to reference Alghazo O et al (2021) Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-61 7 radionuclide therapy prior to radical prostatectomy in men with high -risk localized prostate cancer (LuTectomy study). J Clin Oncol 39(6):264–264CrossRef
Alghazo O et al (2021) Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-61 7 radionuclide therapy prior to radical prostatectomy in men with high -risk localized prostate cancer (LuTectomy study). J Clin Oncol 39(6):264–264CrossRef
26.
go back to reference Tagawa ST et al (2023) 2023 PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 41(16):TPS5116–TPS5116CrossRef
Tagawa ST et al (2023) 2023 PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 41(16):TPS5116–TPS5116CrossRef
27.
go back to reference Oprea-Lager D-E et al (2024) European association of nuclear medicine focus 5: consensus on molecular imaging and theranostics in prostate cancer. Eur Urol 85(1):49–60PubMedCrossRef
Oprea-Lager D-E et al (2024) European association of nuclear medicine focus 5: consensus on molecular imaging and theranostics in prostate cancer. Eur Urol 85(1):49–60PubMedCrossRef
28.
go back to reference Calais J et al (2023) Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treat Rev 115:102524PubMedCrossRef
Calais J et al (2023) Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treat Rev 115:102524PubMedCrossRef
29.
go back to reference Zhang J et al (2023) Rapid tumor washout of 177 Lu-PSMA radioligand in renal cell Carcinoma. Clin Nucl Med 48(8):732–734PubMedCrossRef
Zhang J et al (2023) Rapid tumor washout of 177 Lu-PSMA radioligand in renal cell Carcinoma. Clin Nucl Med 48(8):732–734PubMedCrossRef
30.
go back to reference Sok C et al (2023) Management of gastric neuroendocrine tumors: a review. Ann Surg Oncol 13(3):1509–1518CrossRef
Sok C et al (2023) Management of gastric neuroendocrine tumors: a review. Ann Surg Oncol 13(3):1509–1518CrossRef
31.
go back to reference Enzler T, Fojo T (2017) Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Semin Oncol 44(2):141–156PubMedCrossRef
Enzler T, Fojo T (2017) Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Semin Oncol 44(2):141–156PubMedCrossRef
32.
go back to reference Vaisman F et al (2015) Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin Nucl Med 40(2):123–127PubMedCrossRef
Vaisman F et al (2015) Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin Nucl Med 40(2):123–127PubMedCrossRef
33.
go back to reference Wild D et al (2023) A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging 51(1):183–195PubMedPubMedCentralCrossRef
Wild D et al (2023) A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging 51(1):183–195PubMedPubMedCentralCrossRef
34.
go back to reference Strosberg JR et al (2021) 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752–1763PubMedCrossRef
Strosberg JR et al (2021) 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752–1763PubMedCrossRef
35.
go back to reference Durma AD et al (2023) Radioligand therapy with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in patients with neuroendocrine neoplasms of unknown locations, or locations other than the midgut and pancreas as primaries in a G1, G2 and G3 grade. Pharmaceuticals (Basel, Switzerland) 16(9):1205PubMedCrossRef
Durma AD et al (2023) Radioligand therapy with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in patients with neuroendocrine neoplasms of unknown locations, or locations other than the midgut and pancreas as primaries in a G1, G2 and G3 grade. Pharmaceuticals (Basel, Switzerland) 16(9):1205PubMedCrossRef
36.
go back to reference Saracyn M et al (2023) Renal disturbances during and after radioligand therapy of neuroendocrine tumors-extended analysis of potential acute and chronic complications. Int J Mol Sci 24(8):7508PubMedPubMedCentralCrossRef
Saracyn M et al (2023) Renal disturbances during and after radioligand therapy of neuroendocrine tumors-extended analysis of potential acute and chronic complications. Int J Mol Sci 24(8):7508PubMedPubMedCentralCrossRef
37.
go back to reference Vag T et al (2016) First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med 57(5):741–746PubMedCrossRef
Vag T et al (2016) First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med 57(5):741–746PubMedCrossRef
38.
go back to reference Gourni E et al (2011) PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 52(11):1803–1810PubMedCrossRef
Gourni E et al (2011) PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 52(11):1803–1810PubMedCrossRef
39.
go back to reference Fath MA et al (2024) Chemokine receptor CXCR4 radioligand targeted therapy using 177lutetium-pentixather for pulmonary neuroendocrine cancers. Radiat Res 201(1):35–47PubMedPubMedCentral
Fath MA et al (2024) Chemokine receptor CXCR4 radioligand targeted therapy using 177lutetium-pentixather for pulmonary neuroendocrine cancers. Radiat Res 201(1):35–47PubMedPubMedCentral
40.
go back to reference Buck AK et al (2022) CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 49(12):4133–4144PubMedPubMedCentralCrossRef
Buck AK et al (2022) CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 49(12):4133–4144PubMedPubMedCentralCrossRef
41.
go back to reference Buck AK et al (2023) C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma. J Nucl Med : Off Publ, Soc Nucl Med 64(1):34–39CrossRef
Buck AK et al (2023) C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma. J Nucl Med : Off Publ, Soc Nucl Med 64(1):34–39CrossRef
42.
go back to reference Schwenck J et al (2023) Advances in PET imaging of cancer. Nat Rev Cancer 23(7):474–490PubMedCrossRef
Schwenck J et al (2023) Advances in PET imaging of cancer. Nat Rev Cancer 23(7):474–490PubMedCrossRef
43.
go back to reference Gao Y et al (2023) Functional nodules in primary aldosteronism: identification of CXCR4 expression with (68)Ga-pentixafor PET/CT. Eur Radiol 33(2):996–1003PubMedCrossRef
Gao Y et al (2023) Functional nodules in primary aldosteronism: identification of CXCR4 expression with (68)Ga-pentixafor PET/CT. Eur Radiol 33(2):996–1003PubMedCrossRef
44.
go back to reference Ding J et al (2022) Usefulness of 68 Ga-Pentixafor PET/CT on diagnosis and management of cushing syndrome. Clin Nucl Med 47(8):669–676PubMedCrossRef
Ding J et al (2022) Usefulness of 68 Ga-Pentixafor PET/CT on diagnosis and management of cushing syndrome. Clin Nucl Med 47(8):669–676PubMedCrossRef
45.
go back to reference Koenig T et al (2018) Seeing the unseen: post-infarction inflammation in an isolated right ventricular myocardial infarction visualized by combined cardiac magnetic resonance imaging and chemokine receptor CXCR4-targeted molecular imaging. Eur Heart J 39(11):966PubMedCrossRef
Koenig T et al (2018) Seeing the unseen: post-infarction inflammation in an isolated right ventricular myocardial infarction visualized by combined cardiac magnetic resonance imaging and chemokine receptor CXCR4-targeted molecular imaging. Eur Heart J 39(11):966PubMedCrossRef
46.
go back to reference Weiberg D et al (2018) Clinical molecular imaging of chemokine receptor CXCR4 expression in atherosclerotic plaque using (68)Ga-Pentixafor PET: correlation with cardiovascular risk factors and calcified plaque burden. J Nucl Med 59(2):266–272PubMedCrossRef
Weiberg D et al (2018) Clinical molecular imaging of chemokine receptor CXCR4 expression in atherosclerotic plaque using (68)Ga-Pentixafor PET: correlation with cardiovascular risk factors and calcified plaque burden. J Nucl Med 59(2):266–272PubMedCrossRef
47.
go back to reference Lu X et al (2022) Imaging inflammation in atherosclerosis with CXCR4-Directed [(68)Ga]PentixaFor PET/MRI-compared with [(18)F]FDG PET/MRI. Life (Basel) 12(7):1039PubMed
Lu X et al (2022) Imaging inflammation in atherosclerosis with CXCR4-Directed [(68)Ga]PentixaFor PET/MRI-compared with [(18)F]FDG PET/MRI. Life (Basel) 12(7):1039PubMed
48.
go back to reference Wei L et al (2019) Development of an inflammation imaging tracer, (111)In-DOTA-DAPTA, targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE(-/-) atherosclerosis mouse model. J Nucl Cardiol 26(4):1169–1178PubMedCrossRef
Wei L et al (2019) Development of an inflammation imaging tracer, (111)In-DOTA-DAPTA, targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE(-/-) atherosclerosis mouse model. J Nucl Cardiol 26(4):1169–1178PubMedCrossRef
49.
go back to reference Liu Y et al (2016) Noninvasive imaging of CCR2(+) cells in ischemia-reperfusion injury after lung transplantation. Am J Transplant 16(10):3016–3023PubMedPubMedCentralCrossRef
Liu Y et al (2016) Noninvasive imaging of CCR2(+) cells in ischemia-reperfusion injury after lung transplantation. Am J Transplant 16(10):3016–3023PubMedPubMedCentralCrossRef
50.
go back to reference Liu Y et al (2017) PET-based imaging of chemokine receptor 2 in experimental and disease-related lung inflammation. Radiology 283(3):758–768PubMedCrossRef
Liu Y et al (2017) PET-based imaging of chemokine receptor 2 in experimental and disease-related lung inflammation. Radiology 283(3):758–768PubMedCrossRef
51.
go back to reference Lowe SL et al (2021) Donanemab (LY3002813) phase 1b study in alzheimer”s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis 8(4):414–424PubMedCrossRef
Lowe SL et al (2021) Donanemab (LY3002813) phase 1b study in alzheimer”s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis 8(4):414–424PubMedCrossRef
52.
go back to reference Swanson CJ et al (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer”s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 13(1):80PubMedPubMedCentralCrossRef
Swanson CJ et al (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer”s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 13(1):80PubMedPubMedCentralCrossRef
53.
go back to reference Hayato S et al (2022) Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer”s disease. CPT Pharmacomet Syst Pharmacol 11(12):1578–1591CrossRef
Hayato S et al (2022) Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer”s disease. CPT Pharmacomet Syst Pharmacol 11(12):1578–1591CrossRef
54.
go back to reference Zhang M et al (2021) (18)F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: a longitudinal study. EClinicalMedicine 37:100982PubMedPubMedCentralCrossRef
Zhang M et al (2021) (18)F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: a longitudinal study. EClinicalMedicine 37:100982PubMedPubMedCentralCrossRef
55.
go back to reference Auvity S et al (2020) Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. Eur J Nucl Med Mol Imaging 47(2):490–501PubMedCrossRef
Auvity S et al (2020) Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. Eur J Nucl Med Mol Imaging 47(2):490–501PubMedCrossRef
56.
go back to reference Kim MY (2023) CXCR4 to improve both T cell homing and function. Blood 141(21):2546–2547PubMedCrossRef
Kim MY (2023) CXCR4 to improve both T cell homing and function. Blood 141(21):2546–2547PubMedCrossRef
57.
go back to reference Linde P et al (2021) Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach. Cancer Imaging 21(1):22PubMedPubMedCentralCrossRef
Linde P et al (2021) Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach. Cancer Imaging 21(1):22PubMedPubMedCentralCrossRef
58.
go back to reference Lapa C et al (2016) (68)Ga-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in glioblastoma. Theranostics 6(3):428–434PubMedPubMedCentralCrossRef
Lapa C et al (2016) (68)Ga-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in glioblastoma. Theranostics 6(3):428–434PubMedPubMedCentralCrossRef
59.
go back to reference Lapa C et al (2016) [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer–initial experience. Oncotarget 7(8):9288–9295PubMedPubMedCentralCrossRef
Lapa C et al (2016) [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer–initial experience. Oncotarget 7(8):9288–9295PubMedPubMedCentralCrossRef
60.
go back to reference Heinze B et al (2018) Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension 71(2):317–325PubMedCrossRef
Heinze B et al (2018) Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension 71(2):317–325PubMedCrossRef
61.
go back to reference Ding J et al (2020) Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging 47(11):2656–2665PubMedCrossRef
Ding J et al (2020) Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging 47(11):2656–2665PubMedCrossRef
62.
go back to reference Dusi V et al (2016) Chemokines and heart disease: a network connecting cardiovascular biology to immune and autonomic nervous systems. Mediators Inflamm 2016:5902947PubMedPubMedCentralCrossRef
Dusi V et al (2016) Chemokines and heart disease: a network connecting cardiovascular biology to immune and autonomic nervous systems. Mediators Inflamm 2016:5902947PubMedPubMedCentralCrossRef
63.
go back to reference Damås JK et al (2000) Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 47(4):778–787PubMedCrossRef
Damås JK et al (2000) Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 47(4):778–787PubMedCrossRef
64.
go back to reference Chen Y (2023) Epigenetic regulation of chemokine (CC-motif) ligand 2 in inflammatory. Cell Proliferation 83(2):e13428CrossRef
Chen Y (2023) Epigenetic regulation of chemokine (CC-motif) ligand 2 in inflammatory. Cell Proliferation 83(2):e13428CrossRef
65.
go back to reference Quinones MP et al (2004) Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest 113(6):856–866PubMedPubMedCentralCrossRef
Quinones MP et al (2004) Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest 113(6):856–866PubMedPubMedCentralCrossRef
66.
go back to reference El Khoury J et al (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13(4):432–438PubMedCrossRef
El Khoury J et al (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13(4):432–438PubMedCrossRef
67.
go back to reference Gelman AE et al (2010) CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation. Am J Transplant 10(5):1189–1199PubMedPubMedCentralCrossRef
Gelman AE et al (2010) CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation. Am J Transplant 10(5):1189–1199PubMedPubMedCentralCrossRef
68.
go back to reference Auvynet C et al (2016) ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. Faseb j 30(6):2370–2381PubMedCrossRef
Auvynet C et al (2016) ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. Faseb j 30(6):2370–2381PubMedCrossRef
69.
go back to reference Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer”s disease. Lancet 368(9533):387–403PubMedCrossRef
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer”s disease. Lancet 368(9533):387–403PubMedCrossRef
70.
go back to reference McKhann GM et al (2011) The diagnosis of dementia due to Alzheimer”s disease: recommendations from the National Institute on Aging-Alzheimer”s association workgroups on diagnostic guidelines for Alzheimer”s disease. Alzheimers Dement 7(3):263–269PubMedCrossRef
McKhann GM et al (2011) The diagnosis of dementia due to Alzheimer”s disease: recommendations from the National Institute on Aging-Alzheimer”s association workgroups on diagnostic guidelines for Alzheimer”s disease. Alzheimers Dement 7(3):263–269PubMedCrossRef
71.
go back to reference Blennow K et al (2015) Amyloid biomarkers in Alzheimer”s disease. Trends Pharmacol Sci 36(5):297–309PubMedCrossRef
Blennow K et al (2015) Amyloid biomarkers in Alzheimer”s disease. Trends Pharmacol Sci 36(5):297–309PubMedCrossRef
72.
go back to reference Tamagno E et al (2018) The unexpected role of Aβ1-42 monomers in the pathogenesis of alzheimer”s disease. J Alzheimer”s Dis : JAD 62(3):1241–1245PubMedCrossRef
Tamagno E et al (2018) The unexpected role of Aβ1-42 monomers in the pathogenesis of alzheimer”s disease. J Alzheimer”s Dis : JAD 62(3):1241–1245PubMedCrossRef
73.
go back to reference Lord A et al (2009) An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer”s disease. Neurobiol Dis 36(3):425–434PubMedCrossRef
Lord A et al (2009) An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer”s disease. Neurobiol Dis 36(3):425–434PubMedCrossRef
74.
go back to reference Oh H et al (2015) Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly. Neurobiol Aging 36(12):3247–3254PubMedPubMedCentralCrossRef
Oh H et al (2015) Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly. Neurobiol Aging 36(12):3247–3254PubMedPubMedCentralCrossRef
75.
go back to reference Ruan D, Sun L (2023) Amyloid-β PET in Alzheimer”s disease: a systematic review and Bayesian meta-analysis. Brain Behav 13(1):e2850PubMedCrossRef
Ruan D, Sun L (2023) Amyloid-β PET in Alzheimer”s disease: a systematic review and Bayesian meta-analysis. Brain Behav 13(1):e2850PubMedCrossRef
76.
go back to reference Wilson GD et al (2020) Low dose brain irradiation reduces amyloid-β and Tau in 3xTg-AD Mice. J Alzheimer”s Dis : JAD 75(1):15–21PubMedCrossRef
Wilson GD et al (2020) Low dose brain irradiation reduces amyloid-β and Tau in 3xTg-AD Mice. J Alzheimer”s Dis : JAD 75(1):15–21PubMedCrossRef
77.
go back to reference Ceyzériat K et al (2022) Low-dose radiation therapy reduces amyloid load in young 3xTg-AD Mice. J Alzheimer”s Dis : JAD 86(2):641–653PubMedCrossRef
Ceyzériat K et al (2022) Low-dose radiation therapy reduces amyloid load in young 3xTg-AD Mice. J Alzheimer”s Dis : JAD 86(2):641–653PubMedCrossRef
78.
go back to reference Rezai AR et al (2023) Focused ultrasound-mediated blood-brain barrier opening in Alzheimer”s disease: long-term safety, imaging, and cognitive outcomes. J Neurosurg 139(1):275–283PubMedCrossRef
Rezai AR et al (2023) Focused ultrasound-mediated blood-brain barrier opening in Alzheimer”s disease: long-term safety, imaging, and cognitive outcomes. J Neurosurg 139(1):275–283PubMedCrossRef
79.
go back to reference Jeong H et al (2022) Short-term efficacy of transcranial focused ultrasound to the hippocampus in alzheimer”s disease: a preliminary study. J Pers Med 12(2):250PubMedPubMedCentralCrossRef
Jeong H et al (2022) Short-term efficacy of transcranial focused ultrasound to the hippocampus in alzheimer”s disease: a preliminary study. J Pers Med 12(2):250PubMedPubMedCentralCrossRef
80.
go back to reference Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15(4):275–292PubMedCrossRef
Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15(4):275–292PubMedCrossRef
81.
go back to reference Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104(1):29–45PubMedCrossRef
Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104(1):29–45PubMedCrossRef
82.
go back to reference Henderson JT, Piquette-Miller M (2015) Blood-brain barrier: an impediment to neuropharmaceuticals. Clin Pharmacol Ther 97(4):308–313PubMedCrossRef
Henderson JT, Piquette-Miller M (2015) Blood-brain barrier: an impediment to neuropharmaceuticals. Clin Pharmacol Ther 97(4):308–313PubMedCrossRef
83.
go back to reference Shadmani N et al (2023) Enhancing methotrexate delivery in the brain by mesoporous silica nanoparticles functionalized with cell-penetrating peptide using in vivo and ex vivo monitoring. Mol Pharm 20(3):1531–1548PubMedCrossRef
Shadmani N et al (2023) Enhancing methotrexate delivery in the brain by mesoporous silica nanoparticles functionalized with cell-penetrating peptide using in vivo and ex vivo monitoring. Mol Pharm 20(3):1531–1548PubMedCrossRef
84.
go back to reference Pawar S et al (2024) Tau-targeting nanoparticles for treatment of Alzheimer's disease. Exploration.20230137
Pawar S et al (2024) Tau-targeting nanoparticles for treatment of Alzheimer's disease. Exploration.20230137
85.
go back to reference Wang W et al (2021) Coassembled chitosan-hyaluronic acid nanoparticles as a theranostic agent targeting alzheimer”s β-amyloid. ACS Appl Mater Interfaces 13(47):55879–55889PubMedCrossRef
Wang W et al (2021) Coassembled chitosan-hyaluronic acid nanoparticles as a theranostic agent targeting alzheimer”s β-amyloid. ACS Appl Mater Interfaces 13(47):55879–55889PubMedCrossRef
86.
go back to reference Sabir F, Ismail R, Csoka I (2020) Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug Discov Today 25(1):185–194PubMedCrossRef
Sabir F, Ismail R, Csoka I (2020) Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug Discov Today 25(1):185–194PubMedCrossRef
87.
go back to reference Li W et al (2023) Visualizing reactive astrocytes: Positron emission tomography imaging ligands for imidazoline-2 binding sites. View 4(6):20230037CrossRef
Li W et al (2023) Visualizing reactive astrocytes: Positron emission tomography imaging ligands for imidazoline-2 binding sites. View 4(6):20230037CrossRef
88.
go back to reference Heemels MT (2016) Neurodegenerative diseases. Nature 539(7628):179PubMedCrossRef
Heemels MT (2016) Neurodegenerative diseases. Nature 539(7628):179PubMedCrossRef
89.
go back to reference Rosenberg A et al (2020) Multidomain interventions to prevent cognitive impairment, alzheimer”s disease, and dementia: from FINGER to world-wide FINGERS. J Prev Alzheimers Dis 7(1):29–36PubMedCrossRef
Rosenberg A et al (2020) Multidomain interventions to prevent cognitive impairment, alzheimer”s disease, and dementia: from FINGER to world-wide FINGERS. J Prev Alzheimers Dis 7(1):29–36PubMedCrossRef
90.
go back to reference Mwema A, Muccioli GG, Des Rieux A (2023) Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis. J Control Release 364:435–457PubMedCrossRef
Mwema A, Muccioli GG, Des Rieux A (2023) Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis. J Control Release 364:435–457PubMedCrossRef
91.
go back to reference Yang JK et al (2019) Reaction kinetics-mediated control over silver nanogap shells as surface-enhanced raman scattering nanoprobes for detection of alzheimer”s disease biomarkers. Small 15(19):e1900613PubMedCrossRef
Yang JK et al (2019) Reaction kinetics-mediated control over silver nanogap shells as surface-enhanced raman scattering nanoprobes for detection of alzheimer”s disease biomarkers. Small 15(19):e1900613PubMedCrossRef
92.
go back to reference Cui Z et al (2005) Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer”s and other CNS diseases. Eur J Pharm Biopharm 59(2):263–272PubMedCrossRef
Cui Z et al (2005) Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer”s and other CNS diseases. Eur J Pharm Biopharm 59(2):263–272PubMedCrossRef
93.
go back to reference Govindarajan K, Kar S (2023) Correction: detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer”s disease. J Nanobiotechnology 21(1):251PubMedPubMedCentralCrossRef
Govindarajan K, Kar S (2023) Correction: detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer”s disease. J Nanobiotechnology 21(1):251PubMedPubMedCentralCrossRef
94.
go back to reference Bouhrara M et al (2024) Association of Plasma Markers of Alzheimer's Disease, Neurodegeneration, and Neuroinflammation with the Choroid Plexus Integrity in Aging. Aging Dis 15(5):2230–2240PubMedPubMedCentral
Bouhrara M et al (2024) Association of Plasma Markers of Alzheimer's Disease, Neurodegeneration, and Neuroinflammation with the Choroid Plexus Integrity in Aging. Aging Dis 15(5):2230–2240PubMedPubMedCentral
95.
go back to reference Corot C et al (2004) Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 39(10):619–625PubMedCrossRef
Corot C et al (2004) Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 39(10):619–625PubMedCrossRef
96.
go back to reference Weinstein JS et al (2010) Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 30(1):15–35PubMedCrossRef
Weinstein JS et al (2010) Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 30(1):15–35PubMedCrossRef
97.
go back to reference Yavarpour-Bali H, Ghasemi-Kasman M, Pirzadeh M (2019) Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int J Nanomedicine 14:4449–4460PubMedPubMedCentralCrossRef
Yavarpour-Bali H, Ghasemi-Kasman M, Pirzadeh M (2019) Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int J Nanomedicine 14:4449–4460PubMedPubMedCentralCrossRef
98.
go back to reference Tsao CW et al (2023) Heart disease and stroke statistics-2023 update: a report from the american heart association. Circulation 147(8):e93–e621PubMedCrossRef
Tsao CW et al (2023) Heart disease and stroke statistics-2023 update: a report from the american heart association. Circulation 147(8):e93–e621PubMedCrossRef
99.
go back to reference Li et al (2024) A Novel Circular RNA circITGa9 Predominantly Generated in Human Heart Disease Induces Cardiac Remodeling and Fibrosis. Research (Washington, D.C.), 7: 0303.PubMed
Li et al (2024) A Novel Circular RNA circITGa9 Predominantly Generated in Human Heart Disease Induces Cardiac Remodeling and Fibrosis. Research (Washington, D.C.), 7: 0303.PubMed
100.
go back to reference Wu G et al (2020) A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis. Biomaterials 250:119963PubMedCrossRef
Wu G et al (2020) A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis. Biomaterials 250:119963PubMedCrossRef
101.
go back to reference Tao Y et al (2023) Biomimetic nanomedicines for precise atherosclerosis theranostics. Acta Pharm Sin B 13(11):4442–4460PubMedCrossRef
Tao Y et al (2023) Biomimetic nanomedicines for precise atherosclerosis theranostics. Acta Pharm Sin B 13(11):4442–4460PubMedCrossRef
102.
go back to reference Kopechek JA et al (2019) Ultrasound and microbubble-targeted delivery of a microRNA inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function. Theranostics 9(23):7088–7098PubMedPubMedCentralCrossRef
Kopechek JA et al (2019) Ultrasound and microbubble-targeted delivery of a microRNA inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function. Theranostics 9(23):7088–7098PubMedPubMedCentralCrossRef
103.
go back to reference Libby P (2021) The changing Nature of atherosclerosis: what we thought we knew, what we think we know, and what we have to learn. Eur Heart J 42(47):4781–4782PubMedPubMedCentralCrossRef
Libby P (2021) The changing Nature of atherosclerosis: what we thought we knew, what we think we know, and what we have to learn. Eur Heart J 42(47):4781–4782PubMedPubMedCentralCrossRef
104.
go back to reference Saba L et al (2018) Carotid artery wall imaging: perspective and guidelines from the ASNR vessel wall imaging study group and expert consensus recommendations of the american society of neuroradiology. AJNR Am J Neuroradiol 39(2):E9-e31PubMedPubMedCentralCrossRef
Saba L et al (2018) Carotid artery wall imaging: perspective and guidelines from the ASNR vessel wall imaging study group and expert consensus recommendations of the american society of neuroradiology. AJNR Am J Neuroradiol 39(2):E9-e31PubMedPubMedCentralCrossRef
105.
go back to reference Sun Y et al (2019) Luminescence-resonance-energy-transfer-based luminescence nanoprobe for in situ imaging of CD36 activation and CD36-oxLDL binding in atherogenesis. Anal Chem 91(15):9770–9776PubMedCrossRef
Sun Y et al (2019) Luminescence-resonance-energy-transfer-based luminescence nanoprobe for in situ imaging of CD36 activation and CD36-oxLDL binding in atherogenesis. Anal Chem 91(15):9770–9776PubMedCrossRef
106.
go back to reference Liang M et al (2018) Bioengineered H-ferritin nanocages for quantitative imaging of vulnerable plaques in atherosclerosis. ACS Nano 12(9):9300–9308PubMedCrossRef
Liang M et al (2018) Bioengineered H-ferritin nanocages for quantitative imaging of vulnerable plaques in atherosclerosis. ACS Nano 12(9):9300–9308PubMedCrossRef
107.
go back to reference du Toit LC, Hulisani Demana P, Essop Choonara Y (2022) A nano-enabled biotinylated anti-LDL theranostic system to modulate systemic LDL cholesterol. Int J Pharm 628:122258PubMedCrossRef
du Toit LC, Hulisani Demana P, Essop Choonara Y (2022) A nano-enabled biotinylated anti-LDL theranostic system to modulate systemic LDL cholesterol. Int J Pharm 628:122258PubMedCrossRef
108.
go back to reference Fisher RA, Gollan B, Helaine S (2017) Persistent bacterial infections and persister cells. Nat Rev Microbiol 15(8):453–464PubMedCrossRef
Fisher RA, Gollan B, Helaine S (2017) Persistent bacterial infections and persister cells. Nat Rev Microbiol 15(8):453–464PubMedCrossRef
109.
go back to reference Larsson DGJ, Flach CF (2022) Antibiotic resistance in the environment. Nat Rev Microbiol 20(5):257–269PubMedCrossRef
Larsson DGJ, Flach CF (2022) Antibiotic resistance in the environment. Nat Rev Microbiol 20(5):257–269PubMedCrossRef
110.
go back to reference Igler C, Rolff J, Regoes R (2021) Multi-step vs single-step resistance evolution under different drugs pharmacokinetics and treatment regimens. Elife 10:e64116PubMedPubMedCentralCrossRef
Igler C, Rolff J, Regoes R (2021) Multi-step vs single-step resistance evolution under different drugs pharmacokinetics and treatment regimens. Elife 10:e64116PubMedPubMedCentralCrossRef
111.
go back to reference Lee DE et al (2012) Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev 41(7):2656–2672PubMedCrossRef
Lee DE et al (2012) Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev 41(7):2656–2672PubMedCrossRef
112.
go back to reference Bonam SR et al (2021) Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today 36:101051PubMedCrossRef
Bonam SR et al (2021) Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today 36:101051PubMedCrossRef
113.
go back to reference Himanshu et al (2023) Nanobiotics and the one health approach: boosting the fight against antimicrobial resistance at the nanoscale. Biomolecules 13(8):1182PubMedPubMedCentralCrossRef
Himanshu et al (2023) Nanobiotics and the one health approach: boosting the fight against antimicrobial resistance at the nanoscale. Biomolecules 13(8):1182PubMedPubMedCentralCrossRef
114.
go back to reference Nasiruddin M, Neyaz MK, Das S (2017) Nanotechnology-based approach in tuberculosis treatment. Tuberc Res Treat 2017:4920209PubMedPubMedCentral
Nasiruddin M, Neyaz MK, Das S (2017) Nanotechnology-based approach in tuberculosis treatment. Tuberc Res Treat 2017:4920209PubMedPubMedCentral
115.
go back to reference Gusdon AM et al (2022) Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. Sci Transl Med 14(654):eabo2652PubMedCrossRef
Gusdon AM et al (2022) Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. Sci Transl Med 14(654):eabo2652PubMedCrossRef
116.
go back to reference Jiang L, Ding L, Liu G (2023) Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections. Theranostics 13(5):1545–1570PubMedPubMedCentralCrossRef
Jiang L, Ding L, Liu G (2023) Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections. Theranostics 13(5):1545–1570PubMedPubMedCentralCrossRef
117.
go back to reference Xie S et al (2017) Design and synthesis of theranostic antibiotic nanodrugs that display enhanced antibacterial activity and luminescence. Proc Natl Acad Sci USA 114(32):8464–8469PubMedPubMedCentralCrossRef
Xie S et al (2017) Design and synthesis of theranostic antibiotic nanodrugs that display enhanced antibacterial activity and luminescence. Proc Natl Acad Sci USA 114(32):8464–8469PubMedPubMedCentralCrossRef
118.
go back to reference Robertson MS et al (2024) Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone. La Radiologia Medica
Robertson MS et al (2024) Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone. La Radiologia Medica
119.
go back to reference Chan TG et al (2020) Combination strategies to improve targeted radionuclide therapy. J Nucl Med 61(11):1544–1552PubMedPubMedCentralCrossRef
Chan TG et al (2020) Combination strategies to improve targeted radionuclide therapy. J Nucl Med 61(11):1544–1552PubMedPubMedCentralCrossRef
120.
go back to reference Nonnekens J et al (2016) Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics 6(11):1821–1832PubMedPubMedCentralCrossRef
Nonnekens J et al (2016) Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics 6(11):1821–1832PubMedPubMedCentralCrossRef
121.
go back to reference Davodabadi F et al (2023) Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol 958:176013PubMedCrossRef
Davodabadi F et al (2023) Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol 958:176013PubMedCrossRef
122.
go back to reference Jiang N et al.(2024) Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. La Radiol Med 129(4):631–642.CrossRef
Jiang N et al.(2024) Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. La Radiol Med 129(4):631–642.CrossRef
123.
go back to reference Claringbold PG et al (2011) Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38(2):302–311PubMedCrossRef
Claringbold PG et al (2011) Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38(2):302–311PubMedCrossRef
124.
go back to reference Herbertson RA et al (2014) Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. J Nucl Med 55(4):534–539PubMedCrossRef
Herbertson RA et al (2014) Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. J Nucl Med 55(4):534–539PubMedCrossRef
125.
go back to reference Abascal Junquera JM et al (2023) A drop-in gamma probe for minimally invasive sentinel lymph node dissection in prostate cancer: preclinical evaluation and interim results from a multicenter clinical trial. Clin Nucl Med 48(3):213–220PubMedCrossRef
Abascal Junquera JM et al (2023) A drop-in gamma probe for minimally invasive sentinel lymph node dissection in prostate cancer: preclinical evaluation and interim results from a multicenter clinical trial. Clin Nucl Med 48(3):213–220PubMedCrossRef
126.
go back to reference Sun N et al (2019) (131)I-labeled polyethylenimine-entrapped gold nanoparticles for targeted tumor SPECT/CT imaging and radionuclide therapy. Int J Nanomed 14:4367–4381CrossRef
Sun N et al (2019) (131)I-labeled polyethylenimine-entrapped gold nanoparticles for targeted tumor SPECT/CT imaging and radionuclide therapy. Int J Nanomed 14:4367–4381CrossRef
127.
go back to reference Varani M et al (2022) Methods for radiolabelling nanoparticles: SPECT Use (Part 1). Biomolecules 12(10):1522PubMedPubMedCentralCrossRef
Varani M et al (2022) Methods for radiolabelling nanoparticles: SPECT Use (Part 1). Biomolecules 12(10):1522PubMedPubMedCentralCrossRef
128.
go back to reference Pellico J, Gawne PJ, de Rosales RT (2021) Radiolabelling of nanomaterials for medical imaging and therapy. Chem Soc Rev 50(5):3355–3423PubMedCrossRef
Pellico J, Gawne PJ, de Rosales RT (2021) Radiolabelling of nanomaterials for medical imaging and therapy. Chem Soc Rev 50(5):3355–3423PubMedCrossRef
129.
go back to reference Wu J (2021) The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med 11(8):771PubMedPubMedCentralCrossRef
Wu J (2021) The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med 11(8):771PubMedPubMedCentralCrossRef
Metadata
- Title
- Expanding horizons in theragnostics: from oncology to multidisciplinary applications
- Authors
-
Ruicheng Wu
Weizhen Zhu
Fanglin Shao
Jie Wang
Dengxiong Li
Zhouting Tuo
Koo Han Yoo
Dilinaer Wusiman
Ziyu Shu
Wenjing Ge
Yubo Yang
Mang Ke
Wuran Wei
Susan Heavey
William C. Cho
Dechao Feng
- Publication date
- 05-03-2025
- Publisher
- Springer Milan
- Published in
-
La radiologia medica
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983 - DOI
- https://doi.org/10.1007/s11547-025-01971-7